Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 1.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,422,212 shares of the company’s stock after buying an additional 500,000 shares during the period. Teva Pharmaceutical Industries comprises about 9.6% of Migdal Insurance & Financial Holdings Ltd.’s holdings, making the stock its largest holding. Migdal Insurance & Financial Holdings Ltd.’s holdings in Teva Pharmaceutical Industries were worth $1,561,120,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Parallel Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 8.7% in the third quarter. Parallel Advisors LLC now owns 4,626 shares of the company’s stock valued at $183,000 after buying an additional 370 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 7.1% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 7,311 shares of the company’s stock valued at $248,000 after buying an additional 483 shares during the period. First Trust Advisors LP lifted its stake in Teva Pharmaceutical Industries by 5.9% during the 1st quarter. First Trust Advisors LP now owns 9,619 shares of the company’s stock worth $290,000 after acquiring an additional 539 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 64.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock worth $50,000 after acquiring an additional 647 shares in the last quarter. Finally, Victrix Investment Advisors lifted its stake in Teva Pharmaceutical Industries by 9.5% during the 2nd quarter. Victrix Investment Advisors now owns 7,850 shares of the company’s stock worth $266,000 after acquiring an additional 681 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Teva Pharmaceutical Industries
In other Teva Pharmaceutical Industries news, insider Brian Savage sold 7,342 shares of the company’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the sale, the insider owned 8,500 shares in the company, valued at $330,225. This represents a 46.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Richard Daniell sold 25,000 shares of the company’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $42.91, for a total value of $1,072,750.00. Following the sale, the executive vice president owned 55,755 shares in the company, valued at approximately $2,392,447.05. This trade represents a 30.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 715,945 shares of company stock valued at $29,061,351 in the last 90 days. Insiders own 0.54% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on TEVA shares. TD Cowen raised their target price on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the company a “buy” rating in a report on Wednesday, November 4th. Piper Sandler boosted their price target on shares of Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an “overweight” rating in a research note on Thursday. JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. HC Wainwright began coverage on shares of Teva Pharmaceutical Industries in a research report on Monday, November 2nd. They set a “buy” rating and a $52.00 price target on the stock. Finally, UBS Group raised their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, September 4th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.15.
Check Out Our Latest Stock Report on TEVA
Teva Pharmaceutical Industries Stock Up 2.0%
Shares of NYSE:TEVA traded up $0.87 during trading on Friday, hitting $44.52. The company’s stock had a trading volume of 7,562,490 shares, compared to its average volume of 6,968,955. The business has a 50 day moving average price of $40.16 and a two-hundred day moving average price of $35.07. The company has a market capitalization of $51.88 billion, a PE ratio of 103.53, a P/E/G ratio of 4.09 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.74 and a current ratio of 0.95. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $24.01 and a fifty-two week high of $44.57.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The business had revenue of $4.39 billion for the quarter, compared to analyst estimates of $4.23 billion. During the same quarter in the prior year, the company earned $0.78 earnings per share. The company’s revenue was down 1.9% on a year-over-year basis. As a group, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current fiscal year.
Recent Teva Pharmaceutical Industries Headlines
Here are a few of the latest headlines about TEVA:
- Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and maintained an Overweight rating, pointing to potential upside. HC Wainwright also issued a positive forecast for Teva’s FY2026 earnings, though the report provided no further details. Piper Sandler analyst rating HC Wainwright forecast
- Positive Sentiment: At its R&D Day, Teva outlined a target of $6–7 billion in innovative-medicines revenue by 2030 and highlighted potential first-in-class pipeline treatments, including for Tourette syndrome, celiac disease and intestinal scarring. These are longer-term opportunities, not guaranteed results. Teva R&D Day announcement
- Negative Sentiment: CEO Richard Francis sold 250,000 shares for about $10.56 million, reducing his direct ownership by 21.23%. EVP Richard Daniell also sold shares in two reported transactions—20,003 shares on Nov. 11 and 25,000 on Nov. 9—cutting his reported stake. Insider selling can weigh on sentiment, although it does not by itself establish the executives’ view of Teva’s prospects. CEO SEC filing EVP SEC filing
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
See Also
- Five stocks we like better than Teva Pharmaceutical Industries
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
